Analysts Set R1 RCM Inc. (NASDAQ:RCM) PT at $15.83

Shares of R1 RCM Inc. (NASDAQ:RCM) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $15.83.

A number of equities research analysts have recently weighed in on RCM shares. Citigroup raised R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Wednesday, March 20th. Truist Financial restated a “hold” rating and set a $16.00 price target on shares of R1 RCM in a report on Monday, April 1st. Guggenheim reduced their price target on R1 RCM from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, April 5th. Royal Bank of Canada restated an “outperform” rating and set a $19.00 price target on shares of R1 RCM in a report on Friday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of R1 RCM in a report on Wednesday, April 10th.

R1 RCM Trading Up 0.5 %

Shares of RCM stock opened at $12.56 on Monday. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.78. The business has a 50-day moving average price of $12.43 and a two-hundred day moving average price of $11.88. R1 RCM has a 12-month low of $8.87 and a 12-month high of $18.70. The firm has a market cap of $5.29 billion, a P/E ratio of -157.00 and a beta of 0.86.

R1 RCM (NASDAQ:RCM) last released its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The company had revenue of $603.90 million during the quarter, compared to the consensus estimate of $612.88 million. R1 RCM’s revenue was up 10.7% on a year-over-year basis. Equities analysts anticipate that R1 RCM will post -0.17 EPS for the current fiscal year.

Institutional Trading of R1 RCM

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Boston Partners grew its stake in shares of R1 RCM by 4,976.6% in the 1st quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock worth $32,784,000 after buying an additional 2,519,739 shares during the last quarter. Zimmer Partners LP bought a new position in R1 RCM in the 1st quarter valued at approximately $3,398,000. First Light Asset Management LLC lifted its position in R1 RCM by 212.8% in the 1st quarter. First Light Asset Management LLC now owns 2,552,325 shares of the healthcare provider’s stock valued at $32,874,000 after acquiring an additional 1,736,346 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in R1 RCM by 5.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 89,342 shares of the healthcare provider’s stock valued at $1,151,000 after acquiring an additional 4,670 shares in the last quarter. Finally, BOKF NA bought a new position in R1 RCM in the 1st quarter valued at approximately $1,189,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.